Janux Therapeutics

formerly JanuxIPO

Novel T Cell Immunotherapies

Public · La Jolla, United States · Founded 2017 · $181.0M raised

Employees
51–200
Founded
2017
Business Model
B2B
Total Funding
$181.0M
Last Round
$125.0M Series BApr 2021
Rounds
2
Type
Public

About

Janux Therapeutics is a clinical-stage biopharmaceutical company developing next-generation T cell immunotherapies based on its proprietary Tumor Activated T Cell Engager (TRACTr) and related platforms. Its pipeline targets solid tumor cancers and autoimmune diseases, with programs including JANX014 (PSMA-targeting) currently in Phase 1 trials. The company is listed on Nasdaq (JANX) and headquartered in La Jolla, California.

Summary

Janux Therapeutics is a Biotech company based in La Jolla, United States, founded in 2017. It has raised $181.0M in total across 2 rounds, most recently a $125.0M Series B round in Apr 2021. Investors include RA Capital Management, Avalon Ventures and OrbiMed.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

IPOJun 2021
$222.9M

Sign up to see all 4 rounds

Series A through IPO — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Janux Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/janux-therapeutics"><img src="https://indexed.vc/api/badge/company/janux-therapeutics" alt="Janux Therapeutics on Indexed.vc" width="260" height="76" /></a>